Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Investment Securities (2016 - 2025)

Amphastar Pharmaceuticals has reported Gains from Investment Securities over the past 13 years, most recently at $434000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $434000.0 for Q4 2025, down 88.23% from a year ago — trailing twelve months through Dec 2025 was $13.4 million (down 19.13% YoY), and the annual figure for FY2025 was $24036.0, down 99.64%.
  • Gains from Investment Securities for Q4 2025 was $434000.0 at Amphastar Pharmaceuticals, down from $6.9 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AMPH hit a ceiling of $8.0 million in Q3 2022 and a floor of $1601.0 in Q1 2023.
  • Median Gains from Investment Securities over the past 5 years was $2.1 million (2021), compared with a mean of $3.2 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 99.93% in 2023 and later soared 139979.54% in 2024.
  • Amphastar Pharmaceuticals' Gains from Investment Securities stood at $7.8 million in 2021, then plummeted by 85.28% to $1.1 million in 2022, then skyrocketed by 368.12% to $5.4 million in 2023, then plummeted by 31.39% to $3.7 million in 2024, then crashed by 88.23% to $434000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $434000.0 (Q4 2025), $6.9 million (Q3 2025), and $2.9 million (Q2 2025) per Business Quant data.